Injectable compositions of triterpenoid antifungals encapsulated in liposomes
AssigneeScynexis, Inc.
InventorRajeshwar Motheram
Life of this patent
Estimating the term…
Abstract
Injectable compositions of single bilayer vesicles encapsulating enfumafungin derived triterpenoid antifungal compounds can be administered intravenously to treat or prevent fungal infections, while having reduced local injection site reactions (ISRs). The enfumafungin derived triterpenoid antifungal compounds are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of fungal infections, such as systemic fungal infections, including those caused by Candida and Aspergillus species.
Claims29
An injectable composition comprising:
- an aqueous phase;
- and
- one or more unilamellar vesicles that each comprise phospholipid and cholesterol, and that each encapsulate a compound of Formula (IIa):
- which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2- dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a, 7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
- or a pharmaceutically acceptable salt or hydrate thereof,
- wherein the one or more unilamellar vesicles are hydrated in the aqueous phase.
A method of making an injectable composition comprising one or more unilamellar vesicles that each encapsulate a compound of Formula (IIa)
- which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2- dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a- propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
- or a pharmaceutically acceptable salt or hydrate thereof,
- the method comprising:
- a) dissolving phospholipid and cholesterol in an aliphatic alcohol having one to five carbon atoms to form a first solution;
- b) dissolving the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof in the first solution to form a second solution;
- c) mixing the second solution;
- d) evaporating the solvent from the second solution to produce a phospholipid-cholesterol dispersion containing the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof;
- e) hydrating the phospholipid-cholesterol dispersion containing the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof with a sugar solution to produce a hydrated suspension;
- and
- f) forming, from the hydrated suspension, one or more unilamellar vesicles that each comprise phospholipid and cholesterol and that encapsulate the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof.
Dependencies are inferred from the claim text.